·      Ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis (MS) ·      Twelfth Breakthrough Therapy…

Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) –…

Successful clinical trial results by Bay Area researchers was released Thursday on a new drug that shows promise to become…

Phase III study meets primary endpoint in debilitating form of multiple sclerosis with no approved treatments Ocrelizumab is the first…

   What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study…

Masitinib Shows Promise in Study For Treating Progressive MS Patients JULY 24, 2015 Progressive multiple sclerosis patients treated with AB…

     Progressive multiple sclerosis is a form of multiple sclerosis that is characterized as having nerve degeneration (the breakdown…

 MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet…

Published June 1, 2015 Ashley Ringstaff, of MS World, asks Dr. Jack Burks, how we can slow progression for those…

The American Academy of Neurology’s (AAN’s) 67th Annual Meeting took place in Washington, DC April 18th-25th. The AAN is an…